Content area


Malignt pleuralt mesoteliom


Sajitha Sophia Sritharan1, 2, Jens Lundby Frandsen2, Øyvind Omland3 & Jens Meldgaard Bruun2

1) Lungemedicinsk Afdeling, Aarhus Universitetshospital 2) Medicinsk Afdeling, Regionshospitalet Randers 3) Det Sundhedsvidenskabelige Fakultet, Klinisk Institut, Arbejdsmedicin, Aalborg Universitetshospital Ugeskr Læger 2018;180:V06170439

Ugeskr Læger 2018;180:V06170439
Blad nummer: 
Malignant pleural mesothelioma

Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. The disease is of importance, since the incidence in Denmark is increasing despite cessation of the use of asbestos in the 1980s. MPM has a long latency period, and the first symptom is often dyspnoea, typically caused by pleural effusion. The diagnosis is a challenge, because cytology often is non-conclusive, and thoracoscopy is needed to obtain biopsies for immunohistochemistry. The occupational history is important, since the patients are entitled to compensation. The treatment is often limited to palliation.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Jens Meyer Svendsen | 17/11
10 kommentarer
af Jens Meyer Svendsen | 17/11
1 Kommentar
af Peter Søndergaard | 17/11
1 Kommentar
af Tom Nygaard Kristensen | 16/11
1 Kommentar
af Susanne Udengaard Gydesen | 16/11
6 kommentarer
af Lars Otto Hutters | 16/11
2 kommentarer
af Mette Cathrine Lauridsen | 16/11
2 kommentarer